This brand name is authorized in Australia, Germany
The drug QUILONUM contains one active pharmaceutical ingredient (API):
|
1
Lithium
UNII 2BMD2GNA4V - LITHIUM CARBONATE
|
|
Little is known about the way the lithium ion can modify neurotransmission within the CNS. Many of the proposed mechanisms have suggested an inhibitory effect on components of various neurotransmitter signalling pathways, such as cyclic AMP formation, cyclic GMP formation, G-proteins or inositol phosphate metabolism. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05AN01 | Lithium | N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AN Lithium |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 8290H |
| Country: DE | Bundesinstitut fĂźr Arzneimittel und Medizinprodukte | Identifier(s): 02524807, 02524813 |
Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
